Pancreatic endocrine tumors (PETs) have long fascinated clinicians and investigators
despite their relative rarity. Their clinical presentation varies depending on whether the …

Proton pump inhibitors (PPI) are one of the most widely used classes of drugs. PPIs have a
very favorable safety profile, and it is unusual for a patient to stop them because of side …

Gastrinomas are neuroendocrine neoplasms, usually located in the duodenum or pancreas,
that secrete gastrin and cause a clinical syndrome known as Zollinger-Ellison syndrome …

Well-differentiated neuroendocrine tumors (NETs) of the stomach and pancreas represent 2
major subtypes of gastrointestinal NETs. Historically, there has been little consensus on the …

Pancreatic endocrine tumors (PETs) have long fascinated clini-cians, because some can
release biologically active hormones that cause distinct syndromes and provide important …

Zollinger-Ellison syndrome (ZES) associated with pancreatic or duodenal gastrinoma is
characterized by gastric acid hypersecretion, which typically leads to gastroesophageal …

Pancreatic endocrine neoplasms (PETs) are uncommon tumors with an annual incidence
less than 1 per 100,000 persons per year in the general population. PETs that produce …

Neuroendocrine tumors (NETs) are rare, slow-growing neo-plasms characterized by their
ability to store and secrete different peptides and neuroamines. 1 Some of these substances …

Multiple endocrine neoplasia type 1 (MEN1) is classically characterized by the development
of functional or nonfunctional hyperplasia or tumors in endocrine tissues (parathyroid …

Pancreatic neuroendocrine tumors (PNETs), a group of endocrine tumors arising in the
pancreas, are among the most common neuroendocrine tumors. The genetic causes of …